The efficacy and safety of lenvatinib plus transarterial chemoembolization in combination with PD-1 antibody in treatment of unresectable recurrent hepatocellular carcinoma: a case series report.
Frontiers in oncology（2023）
摘要
Lenvatinib in combination with TACE and PD-1 antibody is safe and effective in the treatment of unresectable recurrent hepatocellular carcinoma.
更多查看译文
关键词
hepatocellular carcinoma,unresectable recurrent hepatocellular carcinoma,transarterial chemoembolization,lenvatinib
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要